Diabetes Center Investigators Complete First Trial of New Immunotherapy for Type 1 Diabetes

Stephen Gitelman, MD, led the first U.S. safety trial of a new form of immunotherapy for type 1 diabetes

Findings lay groundwork for moving beyond drugs – and their associated toxicities – to treat diabetes

Diabetes Center at UCSF

SAN FRANCISCO (December 8, 2015) -- In a first-in-humans phase 1 clinical trial involving 14 adults with type 1 diabetes (T1D), Diabetes Center investigators demonstrated the safety of a novel cell-based strategy for treating the autoimmune disease. Read more about the trial here.

“The entire Diabetes Center is extremely excited about the Treg trial and its critically important implications for future diabetes therapies. The trial also serves as an excellent example of a homegrown endeavor that originated in a basic science laboratory in the Diabetes Center and eventually culminated in a clinical trial for humans,” says Matthias Hebrok, PhD, director of the Diabetes Center.

“Each day, basic scientists, physicians, and clinical trialists in the Diabetes Center work together toward the same goal: to improve the lives of diabetes patients. The Treg trial is a reflection of this partnership,” added Dr. Hebrok.

For more information, visit diabetes.ucsf.edu.

Caption: Stephen Gitelman, MD, led the first U.S. safety trial of a new form of immunotherapy for type 1 diabetes.

###